AAPS appoints Patrick J. Sinko as Chief Science Officer
19 Oct 2026
The American Association of Pharmaceutical Scientists (AAPS) has appointed Patrick J. Sinko, Ph.D., R.Ph., FAAPS, as Chief Science Officer. In this role, Dr. Sinko will lead the organization’s scientific strategy, guide scientific programming across its in-person and digital platforms, and direct its portfolio of peer-reviewed journals to help AAPS address urgent challenges in drug discovery and development for pharmaceutical scientists across academia, industry, and regulatory agencies worldwide.
Patrick J. Sinko, Ph.D., R.Ph., FAAPS
Scientific strategy and leadership at AAPS
As Chief Science Officer, Dr. Sinko will shape AAPS’s scientific vision, encourage interdisciplinary collaboration, and support cutting-edge scientific programming and publications. His leadership will help the association broaden its reach, strengthen its core scientific offerings, and provide value to its global membership and the wider scientific community.
A former AAPS President and long-standing member, Dr. Sinko brings decades of scientific leadership, academic rigor, and association governance experience to the position.
“AAPS has long been the intellectual home for pharmaceutical scientists across academia, industry, and regulatory agencies,” said Dr. Sinko. “I am honored to step into the Chief Science Officer role to help shape our scientific vision, foster interdisciplinary collaboration, and deliver cutting-edge programming and publications that address the most urgent challenges in drug discovery and development.”
Academic and editorial experience
Dr. Sinko will continue his active academic appointment at Rutgers, The State University of New Jersey. He serves as Distinguished Professor and the Parke-Davis Endowed Chair in Pharmaceutics at the Ernest Mario School of Pharmacy.
He is Editor of Martin’s Physical Pharmacy and Pharmaceutical Sciences, Editor-in-Chief of Pharmaceutics (MDPI), and a member of the Editorial Advisory Boards of numerous scientific journals.
Pharmaceutical science and biotechnology credentials
Dr. Sinko previously co-founded Navicyte and Theraport Biosciences, serving as Chief Science Officer, and was Chief Scientist of Trega Biosciences (NASDAQ: TRGA).
He is an elected Fellow of the American Association for the Advancement of Science (AAAS), AAPS, the Controlled Release Society, and the National Academy of Inventors.
Supporting the next generation of pharmaceutical scientists
Meena Subramanyam, Ph.D., AAPS Immediate Past President, said Dr. Sinko’s scientific expertise and commitment to developing future scientists make him well suited to lead the association’s scientific direction.
“Dr. Sinko’s unwavering commitment to advancing the pharmaceutical sciences, deep understanding of the scientific landscape, and passion for developing the next generation of scientists make him exceptionally well suited for this role. Under his scientific leadership, AAPS will continue to broaden its reach, strengthen its core scientific offerings, and deliver substantial value to our global membership and the wider scientific community.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Tags
Frequently asked questions
Show frequently asked questions
Who has AAPS appointed as Chief Science Officer?
The American Association of Pharmaceutical Scientists (AAPS) appointed Patrick J. Sinko, Ph.D., R.Ph., FAAPS. He will lead AAPS’s scientific strategy, guide programming across in-person and digital platforms, and direct its peer-reviewed journal portfolio.
What experience does Patrick J. Sinko bring to AAPS?
Dr. Sinko is a former AAPS President, Rutgers Distinguished Professor, Parke-Davis Endowed Chair in Pharmaceutics, journal editor, biotechnology co-founder, and former Chief Scientist of Trega Biosciences. He is also an elected Fellow of AAAS, AAPS, the Controlled Release Society, and the National Academy of Inventors.
How will Patrick J. Sinko support pharmaceutical science and drug development?
Dr. Sinko will shape AAPS’s scientific vision, foster interdisciplinary collaboration, and advance programming and publications addressing urgent drug discovery and development challenges. His leadership will support pharmaceutical scientists across academia, industry, and regulatory agencies while helping develop the next generation of scientists.